✦ LIBER ✦

520 Efficacy of Ibodutant, a Selective Antagonist of Neurokinin 2 Receptors, in Irritable Bowel Syndrome With Diarrhoea (IBS-D): The Results of a Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Phase II Study (the IRIS-2)

✍ Scribed by Tack, Jan F.; Dochev, Yavor S.; Bochenek, Anna; Atanasov, Ivan; Horynski, Marek; Lundqvist, Pernille; Schumacher, Kai; Otranto, Isabella; Capriati, Angela; Maggi, Carlo Alberto

Book ID: 122173183
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 639 KB
Volume: 144
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(13)60340-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A twelve-week, randomized, double-blind,

A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome

✍ EDWARDS1, E 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 26 KB

377 A Randomized, Double-Blind, Placebo-

377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

✍ William G. Paterson; Jonathon Springer; Michael O'Mahony; Richard P. Reynolds; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 95 KB